English Spanish Chinese Russian German Japanese Portuguese Hindi Telugu Tamil

Archives de microbiologie clinique

  • ISSN: 1989-8436
  • Indice h du journal: 22
  • Note de citation du journal: 7.55
  • Facteur d’impact du journal: 6.38
Indexé dans
  • Ouvrir la porte J
  • Genamics JournalSeek
  • Le facteur d'impact global (GIF)
  • Initiative d'archives ouvertes
  • Infrastructure nationale des connaissances en Chine (CNKI)
  • Répertoire d'indexation des revues de recherche (DRJI)
  • OCLC - WorldCat
  • Invocation de Proquête
  • Publions
  • MIAR
  • Commission des bourses universitaires
  • Fondation genevoise pour la formation et la recherche médicales
  • Google Scholar
  • Classement des revues Scimago
  • Laboratoires secrets des moteurs de recherche
  • ResearchGate
Voir plus
Partager cette page

Abstrait

Brief Overview on "Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture"

Warren K. Weston*,Jane A. Harness and Aarthi Narayanan

The COVID-19 pandemic remains a pressing global challenge. Worldwide mortality attributable to COVID-19 now exceeds 4 million deaths. There is an urgent need for developing novel therapeutics to treat SARS-CoV-2. Our recent study showed brilacidin, a synthetic small molecule with peptide-like properties, potently inhibits SARS-CoV-2 in cell culture. Additionally, brilacidin exhibited in vitro inhibition in combination with remdesivir, the only FDA-approved drug for treatment of COVID-19. Brilacidin is currently undergoing Phase 2 clinical testing for treatment of moderate-to-severe COVID-19 in hospitalized patients.